All In Biotech

Drug Trial Radar · NCT00089505

NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission

Optimal Combination Therapy After Nevirapine Exposure

Last checked: Nov 19, 2026Latest source record: Oct 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 745 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

745

Actual

Start

Nov 2006

Primary completion

Aug 2010

Study completion Feb 2011

Sponsor

Sponsor type
Research network
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Aug 6, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are commonly included in anti-HIV drug regimens. However, HIV infected women who have previously taken the single dose NNRTI nevirapine (SD NVP) for the prevention of mother-to-child transmission (MTCT) of HIV may not respond as well to NNRTIs as women who have never taken NVP. Another class of anti-HIV drugs, protease inhibitors (PIs), may be more effective for women who have previously taken NNRTIs. This study will compare the effectiveness of NNRTI- and PI-based regimens in women who have taken NVP for prevention of MTCT of HIV. This study will also compare regimens including an NNRTI with regimens including a PI in women who have never taken NVP.

Conditions

  • HIV Infections

Interventions

  • EmtricitabineDrug

    200 mg taken orally

  • Emtricitabine/Tenofovir disoproxil fumarateDrug

    200/300 mg taken orally

  • Lopinavir/RitonavirDrug

    400/100 mg taken orally

  • NevirapineDrug

    200 mg taken orally

  • Tenofovir disoproxil fumarateDrug

    300 mg taken orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time From Randomization to Virologic Failure or Death for Participants Who Had SD NVP Exposure Prior to Study EntryTime frame: Through database cutoff for DSMB review (by October 6, 2008) with median follow-up 72 weeks and range from 0 to 144 weeks.
  2. Time From Randomization to Virologic Failure or Death for Participants Without SD NVP Exposure Prior to Study EntryTime frame: Throughout study with median follow-up 72 weeks and range from 0 to 180 weeks.

Locations

11 sites in 7 countries. Site status is shown where the registry gives one.

  • Molepolole BHP Study Clinic, Scottish Livingstone Hospital

    Bontleng Gaborone, Botswana

  • The Gaborone BHP Study Clinic

    Bontleng, Gaborone, Botswana

  • Moi University International Clnical Trials Unit

    Eldoret, Kenya

  • KMRI / Walter Reed Project Clinical Research Center

    Kericho, Kenya

  • University of North Carolina Project (UNC Project)

    Lilongwe, Malawi

  • Chris Hani Baragwanath Hospital, Johannesburg

    Johannesburg, South Africa

  • University of Witwatersrand

    Johannesburg, South Africa

  • University of KwaZulu Natal

    Durban, KwaZulu-Natal, South Africa

  • Joint Clinical Research Centre (JCRC)

    Kampala, Uganda

  • Centre for Infectious Disease Research in Zambia (CIDRZ)

    Lusaka, Zambia

  • University of Zimbabwe

    Avondale, Harare, Zimbabwe

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.